Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer | Zendy

Mao Lin | Zendy; Mohammed Alnaggar | Zendy; Shuzhen Liang | Zendy; Jibing Chen | Zendy; Kecheng Xu | Zendy; Shihua Dong | Zendy; Duanming Du | Zendy; Lizhi Niu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer

Author(s) -

Mao Lin,

Mohammed Alnaggar,

Shuzhen Liang,

Jibing Chen,

Kecheng Xu,

Shihua Dong,

Duanming Du,

Lizhi Niu

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000490874

Subject(s) - kras , digital polymerase chain reaction , medicine , biomarker , pancreatic cancer , cancer , oncology , stage (stratigraphy) , cancer research , liquid biopsy , polymerase chain reaction , gene , colorectal cancer , biology , paleontology , biochemistry

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, resulting in extremely poor 5-year survival. Late diagnosis of PDAC is mainly due to lack of a reliable method of early detection. Carbohydrate antigen (CA) 19-9 is often used as a tumor biomarker in PDAC; however, the test lacks sensitivity and specificity. Therefore, new sensitive and minimally invasive diagnostic tools are required to detect pancreatic cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research